Clinical pathway for surgical treatment of primary lung cancer (2012 Edition) [0.03%]
原发性肺癌外科治疗临床路径(2012年版)
Xiu-Yi Zhi,Jian-Xing He,Hui Li et al.
Xiu-Yi Zhi et al.
Nicholas Nacca,Castigliano M Bhamidipati,Luke S Yuhico et al.
Nicholas Nacca et al.
A known complication of Amiodarone therapy is Amiodarone induced Pulmonary Toxicity (APT). Several features of this adverse effect make it difficult to diagnosis and treat. The case of a 63-year-old male with classic radiographic and histol...
Wolfgang Hohenforst-Schmidt,Matthias Woitow,Paul Zarogoulidis et al.
Wolfgang Hohenforst-Schmidt et al.
Glomus tumors are uncommon lesions of glomus cell origin with ultrastructural and immunohistochemical features of smooth muscle. In the majority of the cases reported in the literature glomus tumors are benign, but there are some rare cases...
Pneumothorax, an underappreciated complication with an airway exchange catheter [0.03%]
气道交换导管一个被低估的并发症： pneumothorax
Ali M Rashid,Charles Williams,Jason Noble et al.
Ali M Rashid et al.
While airway exchange catheters (AEC) are designed to safely maintain a secure airway and sometimes allow for ventilation while exchanging an endotracheal tube or performing a trial tracheal extubation, their use is sometimes associated wit...
Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis [0.03%]
无肺基础病变的肺类癌肿瘤病灶与其纤维化关系分析
Ping He,Xia Gu,Qinian Wu et al.
Ping He et al.
Pulmonary carcinoid tumorlet is a rare pathology and appears to be always associated with other lesions such as bronchiectasis and fibrosis. While the caus e-effect relationship between tumorlet and the accompanying pathological changes in ...
Takashi Ishikawa,Daisuke Shimizu,Ayako Kito et al.
Takashi Ishikawa et al.
Breast cancer is the most common type of cancer in women. However, it is very rarely manifested as hematologic disorders. A 35-year-old woman was admitted because of disseminated intravascular coagulation. Examinations revealed the presence...
Anti-angiogenic treatments in advanced NSCLC: back to the drawing board [0.03%]
晚期非小细胞肺癌的抗血管生成治疗：重新设计研发策略
Jair Bar,Iris Shiran,Damien Urban et al.
Jair Bar et al.
Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer [0.03%]
达可替尼：非小细胞肺癌HER受体靶向治疗新药
Richard L Carpenter,Hui-Wen Lo
Richard L Carpenter
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? [0.03%]
晚期非小细胞肺癌索拉非尼研究的几年中，是否存在一种将“不成功的治疗和潜在有效的疗法”联系在一起的“纽带”?
Giulio Metro,Vincenzo Minotti,Lucio Crinò
Giulio Metro